IMDX vs LRCX · rev $271.0K vs P/E 71, rev $23.23B
Insight Molecular Diagnostics Inc. (IMDX) versus Lam Research Corp (LRCX) — a side-by-side from cached financials, not a winner call.
Insight Molecular Diagnostics Inc. (IMDX) is a diagnostics & research company listed on US.
Lam Research Corp (LRCX) is a semiconductor equipment & materials company listed on NASDAQ. It is led by Timothy M. Archer.
Latest reported IMDX revenue for 2026-06-30 was $271.0K. Net income was -$15.6M. IMDX currently screens at market cap $0.
Latest reported LRCX revenue for 2026-06-28 was $23.23B. Net income was $7.27B. LRCX currently screens at market cap $467.94B and trailing P/E 70.9.
IMDX currently screens at market cap $0. LRCX currently screens at market cap $467.94B and trailing P/E 70.9.
Not investment advice. Open the IMDX and LRCX stock pages for the full models.
Not investment advice.